| ID Source | ID |
|---|---|
| PubMed CID | 135401477 |
| CHEMBL ID | 54079 |
| CHEBI ID | 170049 |
| SCHEMBL ID | 1202 |
| Synonym |
|---|
| 5-(2-ethoxyphenyl)-1-methyl-3-propyl-6h-pyrazolo[4,3-d]pyrimidin-7-one |
| imidazosagatriazinone |
| 139756-21-1 |
| CHEBI:170049 |
| 5-(2-ethoxyphenyl)-1-methyl-3-propyl-1,4-dihydro-7h-pyrazolo[4,3-d]pyrimidin-7-one |
| MLS000704311 |
| smr000230865 |
| 5-(2-ethoxyphenyl)-1-methyl-3-n-propyl-1,6-dihydro-7h-pyrazolo[4,3-d]-7-pyrimidinone, 97% |
| CHEMBL54079 , |
| bdbm50111899 |
| 5-(2-ethoxyphenyl)-1-methyl-3-propyl-1h-pyrazolo[4,3-d]pyrimidin-7(6h)-one |
| 5-(2-ethoxy-phenyl)-1-methyl-3-propyl-1,6-dihydro-pyrazolo[4,3-d]pyrimidin-7-one |
| FT-0668119 |
| 5-(2-ethoxyphenyl)-1-methyl-3-propyl-4h-pyrazolo[4,3-d]pyrimidin-7-one |
| HMS2511C22 |
| AKOS015911946 |
| 5-(2-ethoxyphenyl)-1-methyl-3-n-propyl-1,6-dihydro-7h-pyrazolo[4,3-d]pyrimidin-7-one |
| uk 088800 |
| 5-(2-ethoxyphenyl)-1-methyl-3-n-propyl-1,6-dihydro-7h-pyrazolo[4,3-d]-7-pyrimidinone |
| SCHEMBL1202 |
| 5-(2-ethoxyphenyl)-1-methyl-3-n-propyl-1,6-dihydro-7h-pyrazolo-[4,3-d]pyrimidin-7-one |
| MXQUEDUMKWBYHI-UHFFFAOYSA-N |
| 2-(2-ethoxy)-phenyl-1-methyl-3-n-propyl-1,6-dihydro-7h-pyrazolo[4,3-d]pyrimidine-7-one |
| 5-(2-ethoxyphenyl)-1-methyl-3-n-propyl-1.6-dihydro-7h-pyrazolo[4,3-d]pyrimidin-7-one |
| 5-(2-ethoxyphenyl)-1-methyl-3-n-propyl-1,6-dihydro-7h-pyrazolo[4,3-d]-pyrimidin-7-one |
| AC-26314 |
| 5-(2-ethoxyphenyl)-1-methyl-3-propyl-1,6-dihydro-7h-pyrazolo[4,3-d]-7-pyrimidinone |
| mfcd03093929 |
| 5-(2-ethoxyphenyl)-1-methyl-3-propyl-1,6-dihydro-7h-pyrazolo[4,3-d]pyrimidin-7-one |
| 5-(2-ethoxyphenyl)-1-methyl-3-propyl-1,6-dihydro-7hpyrazolo(4,3-d)pyrimidin-7-one |
| 5-(2-ethoxyphenyl)-1-methyl-3-propyl-1,6-dihydro-7h-pyrazolo(4,3-d)pyrimidin-7-one |
| uk-088800 |
| 5-(2-ethoxyphenyl)-1,6-dihydro-1-methyl-3-propyl-7h-pyrazolo(4,3-d)pyrimidin-7-one |
| 7h-pyrazolo(4,3-d)pyrimidin-7-one, 5-(2-ethoxyphenyl)-1,4-dihydro-1-methyl-3-propyl- |
| E4M9V1JW7V , |
| 7h-pyrazolo(4,3-d)pyrimidin-7-one, 5-(2-ethoxyphenyl)-1,6-dihydro-1-methyl-3-propyl- |
| unii-e4m9v1jw7v |
| 5-(2-ethoxyphenyl)-1-methyl-3-propyl-1h-pyrazolo(4,3-d)pyrimidin-7(6h)-one |
| DTXSID40358476 |
| 5-(2-ethoxyphenyl)-1-methyl-3n-propyl-1,6-dihydro-7h-pyrazolo[4,3-d]pyrimidin-7-one |
| J-007314 |
| A885952 |
| BCP16444 |
| 5-(2-ethoxyphenyl)-l-methyl-3-n-propyl-1,6-dihydro-7h-pyrazolol- 4,3-dipyrimidin-7-one |
| 7h-pyrazolo[4,3-d]pyrimidin-7-one, 5-(2-ethoxyphenyl)-1,6-dihydro-1-methyl-3-propyl- |
| DS-16277 |
| E1134 |
| 5-(2-ethoxyphenyl)-l-methyl-3-n-propyl-1,6-dihydro-7h-pyrazolol- |
| AMY11145 |
| Q27276861 |
| EN300-7419020 |
| 5-(2-ethoxyphenyl)-1-methyl-3-propyl-1h,6h,7h-pyrazolo[4,3-d]pyrimidin-7-one |
| SY035606 |
| CS-W012052 |
| pde5-in-7 |
| HY-W011336 |
| Z3234901362 |
| Class | Description |
|---|---|
| pyrazolopyrimidine | |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Chain A, Beta-lactamase | Escherichia coli K-12 | Potency | 35.4813 | 0.0447 | 17.8581 | 100.0000 | AID485341 |
| Chain A, Cruzipain | Trypanosoma cruzi | Potency | 39.8107 | 0.0020 | 14.6779 | 39.8107 | AID1476 |
| ClpP | Bacillus subtilis | Potency | 19.9526 | 1.9953 | 22.6730 | 39.8107 | AID651965 |
| ATAD5 protein, partial | Homo sapiens (human) | Potency | 20.5962 | 0.0041 | 10.8903 | 31.5287 | AID504467 |
| aldehyde dehydrogenase 1 family, member A1 | Homo sapiens (human) | Potency | 35.4813 | 0.0112 | 12.4002 | 100.0000 | AID1030 |
| euchromatic histone-lysine N-methyltransferase 2 | Homo sapiens (human) | Potency | 39.8107 | 0.0355 | 20.9770 | 89.1251 | AID504332 |
| 15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1 | Homo sapiens (human) | Potency | 39.8107 | 0.0018 | 15.6638 | 39.8107 | AID894 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| cGMP-specific 3',5'-cyclic phosphodiesterase | Homo sapiens (human) | IC50 (µMol) | 0.0334 | 0.0000 | 1.1843 | 9.6140 | AID157953; AID240761; AID366091 |
| cAMP-specific 3',5'-cyclic phosphodiesterase 4A | Homo sapiens (human) | IC50 (µMol) | 0.5000 | 0.0000 | 1.0680 | 10.0000 | AID160126 |
| Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1A | Homo sapiens (human) | IC50 (µMol) | 0.7900 | 0.2300 | 2.5105 | 10.0000 | AID240757 |
| Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1B | Homo sapiens (human) | IC50 (µMol) | 0.7900 | 0.0000 | 2.1417 | 9.2000 | AID240757 |
| cAMP-specific 3',5'-cyclic phosphodiesterase 4B | Homo sapiens (human) | IC50 (µMol) | 0.5000 | 0.0000 | 1.1040 | 10.0000 | AID160126 |
| cAMP-specific 3',5'-cyclic phosphodiesterase 4C | Homo sapiens (human) | IC50 (µMol) | 0.5000 | 0.0000 | 1.4651 | 10.0000 | AID160126 |
| cAMP-specific 3',5'-cyclic phosphodiesterase 4D | Homo sapiens (human) | IC50 (µMol) | 0.5000 | 0.0000 | 1.1463 | 10.0000 | AID160126 |
| cGMP-inhibited 3',5'-cyclic phosphodiesterase B | Homo sapiens (human) | IC50 (µMol) | 0.5000 | 0.0000 | 2.0724 | 10.0000 | AID159486 |
| Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1C | Homo sapiens (human) | IC50 (µMol) | 0.7900 | 0.2300 | 1.9814 | 9.0000 | AID240757 |
| cGMP-inhibited 3',5'-cyclic phosphodiesterase A | Homo sapiens (human) | IC50 (µMol) | 0.5000 | 0.0003 | 1.9901 | 10.0000 | AID159486 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
| AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
| AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID159486 | Inhibition of Phosphodiesterase 3 | 2002 | Bioorganic & medicinal chemistry letters, Mar-25, Volume: 12, Issue:6 | Imidazo[5,1-f]triazin-4(3H)-ones, a new class of potent PDE 5 inhibitors. |
| AID160126 | Inhibition of Phosphodiesterase 4 | 2002 | Bioorganic & medicinal chemistry letters, Mar-25, Volume: 12, Issue:6 | Imidazo[5,1-f]triazin-4(3H)-ones, a new class of potent PDE 5 inhibitors. |
| AID240761 | Inhibition of phosphodiesterase 5 | 2005 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 15, Issue:17 | Comparison of different heterocyclic scaffolds as substrate analog PDE5 inhibitors. |
| AID158741 | Inhibition of Phosphodiesterase 1 (Not tested) | 2002 | Bioorganic & medicinal chemistry letters, Mar-25, Volume: 12, Issue:6 | Imidazo[5,1-f]triazin-4(3H)-ones, a new class of potent PDE 5 inhibitors. |
| AID656105 | Inhibition of Trypanosoma brucei PDEB1 at 100 uM | 2012 | Bioorganic & medicinal chemistry letters, Apr-01, Volume: 22, Issue:7 | Synthesis and evaluation of human phosphodiesterases (PDE) 5 inhibitor analogs as trypanosomal PDE inhibitors. Part 1. Sildenafil analogs. |
| AID366091 | Inhibition of PDE5 | 2008 | Bioorganic & medicinal chemistry, Aug-15, Volume: 16, Issue:16 | In silico prediction of novel phosphodiesterase type-5 inhibitors derived from Sildenafil, Vardenafil and Tadalafil. |
| AID240757 | Inhibition of phosphodiesterase 1 | 2005 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 15, Issue:17 | Comparison of different heterocyclic scaffolds as substrate analog PDE5 inhibitors. |
| AID157953 | Inhibition of Phosphodiesterase 5 | 2002 | Bioorganic & medicinal chemistry letters, Mar-25, Volume: 12, Issue:6 | Imidazo[5,1-f]triazin-4(3H)-ones, a new class of potent PDE 5 inhibitors. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (44.44) | 29.6817 |
| 2010's | 4 (44.44) | 24.3611 |
| 2020's | 1 (11.11) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 9 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||